Description

History / Background

Tesamorelin is a synthetic peptide that functions as a growth hormone-releasing factor (GHRF) analog. Developed by the pharmaceutical company Theratechnologies, it is primarily known for stimulating the release of growth hormone (GH) from the pituitary gland. Tesamorelin is designed to enhance GH secretion without the side effects commonly associated with direct GH administration.

It was initially studied for its potential to reduce visceral fat in HIV-infected patients with lipodystrophy, a condition characterized by abnormal fat distribution. In 2010, Tesamorelin received FDA approval under the brand name Egrifta for the treatment of excess abdominal fat in these patients.

Research For:

Potential benefits of Tesamorelin include:

1. Reduction of Visceral Fat
   Significantly reduces visceral fat, particularly in individuals with HIV-associated lipodystrophy.

2. Increased Growth Hormone Levels
   Stimulates GH secretion, promoting increased overall growth hormone levels, which can benefit metabolism.

3. Improved Body Composition
   May help improve lean body mass, contributing to a more favorable body composition.

4. Metabolic Health Improvement
   Potential positive effects on insulin sensitivity and lipid profiles, although more research is needed to fully understand these effects.

5. Potential Anti-Aging Effects
   Stimulation of GH release may contribute to improved skin elasticity and vitality, though research is ongoing.

Important Considerations

• Regulatory Status: FDA-approved for treatment of excess abdominal fat in HIV lipodystrophy under the brand Egrifta. Should be used only under medical supervision.

• Side Effects: Common side effects include injection site reactions, headaches, nausea, diarrhea, and abdominal pain. There may also be concerns about increased insulin resistance.

• Healthcare Consultation: Use should be guided by a healthcare professional, particularly because of potential side effects and interactions with other medications.